In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea (HI-443)

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 4, 2007, Pages 218-226

  Uckun, Fatih M ^a,b   Tibbles, Heather ^a   Erbeck, Douglas ^b   Venkatachalam, Taracad K ^a   Qazi, Sanjive ^a,b  

^a Paradigm Pharmaceuticals   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

Anti HIV agent; CAS 258340 15 7; HI 443, in vivo pharmacokinetics, toxicity; Non nucleoside reverse transcriptase inhibitor; N 2 (2 Thiophene)ethyl N 2 (5 bromopyridyl) thiourea

Indexed keywords

HI 443; MACROGOL 400; N' [2 (2 THIOPHENE)ETHYL] N' [2 (5 BROMOPYRIDYL)] THIOUREA; PROPYLENE GLYCOL; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; MOUSE; NONHUMAN;

EID: 34248169700     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296608     Document Type: Article

References (13)

1. Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, et al. N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-3416.
2. Uckun FM, Venkatachalam TK, inventors; Thiophene-ethyl thiourea compounds and use. United States patent 6,124, 324. 2000.
3. Uckun FM, Qazi S, Venkatachalam TK. N′-[2-(2-Thiophene)ethyl]- N′-[2-(5-bromopyridyl)] thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity. Arzneimittel-Forschung (Drug Research). 2007;in press.
4. Uckun FM, Pendergrass S, Qazi S, Venkatachalam TK. In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates. Arzneimittel-Forschung (Drug Research). 2004;54(1):69-77.
5. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):157-162.
6. Richman DD, Johnson VA, Mayers DL. In vitro evaluation of experimental agents for anti-HIV activity. Current Protocols in Immunology. Brooklyn, NY: John Wiley & Sons, 1993:Unit 12.9, 1-21.
7. Uckun FM, Pendergrass S, Venkatachalam TK, Qazi S, Richman D. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob Agents Chemother. 2002 Nov;46(11):3613-3616.
8. Chen XQ, Antman MD, Gesenberg C, Gudmundsson OS. Discovery pharmaceutics-challenges and opportunities. Aaps J. 2006;8(2):E402-408.
9. Uckun FM, Venkatachalam TK, Erbeck D. In vivo pharmacokinetics, metabolism, toxicty, and anti-HIV activity of N′-[2-(2-thiophene)ethyl]- N′-[2-(5-bromopyridyl)] thiourea (HI-443), a potent non-nucleoside reverse transcriptase inhibitor compound. Arzneimittel-Forschung (Drug Research). In press 2007.
10. USP United States Pharmacopea; 2000.
11. Box G, Cox D. An Analysis of Transformations. Journal of the Royal Statistical Society Series B. 1964; Vol. 26: 211-246.
12. SAS Institute Inc. JMP Statistics and Graphics Guide 1995.
13. Martin AN, Bustamante P. Physical pharmacy: physical chemical principles in the pharmaceutical sciences. 4th ed. Philadelphia: Lea & Febiger; 1993.